These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17487749)

  • 1. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
    Ostro D; Cheung K; Kamel-Reid S; Lipton JH
    Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
    [No Abstract]   [Full Text] [Related]  

  • 2. Chromosomal abnormalities in Ph- cells of patients on imatinib.
    McMullin MF; Humphreys M; Byrne J; Russell NH; Cuthbert RJ; O'Dwyer ME
    Blood; 2003 Oct; 102(7):2700-1; author reply 2701. PubMed ID: 14504073
    [No Abstract]   [Full Text] [Related]  

  • 3. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
    Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N
    Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
    Van Den Akker J; Coppo P; Portnoï MF; Barbu V; Bories D; Gorin NC
    Leuk Lymphoma; 2007 Sep; 48(9):1858-65. PubMed ID: 17786726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Kovitz C; Kantarjian H; Garcia-Manero G; Abruzzo LV; Cortes J
    Blood; 2006 Oct; 108(8):2811-3. PubMed ID: 16809614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
    Zaccaria A; Valenti AM; Donti E; Gozzetti A; Ronconi S; Spedicato F
    Haematologica; 2007 Apr; 92(4):564-5. PubMed ID: 17488671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
    Herens C; Baron F; Croisiau C; Tassin F; Bours V
    Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
    Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
    Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
    Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
    [No Abstract]   [Full Text] [Related]  

  • 10. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
    Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
    Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
    [No Abstract]   [Full Text] [Related]  

  • 11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
    Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 14. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 15. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
    Malhotra KP; Sharma CB; Jain J; Grover RK
    J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
    [No Abstract]   [Full Text] [Related]  

  • 16. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Kantarjian HM; Abruzzo LV; O'Brien S; Garcia-Manero G; Verstovsek S; Shan J; Rios MB; Cortes J
    Blood; 2007 Oct; 110(8):2991-5. PubMed ID: 17625066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia.
    Syed NN; Usman M; Adil S; Khurshid M
    Hematol Oncol Stem Cell Ther; 2008; 1(3):166-70. PubMed ID: 20063547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
    Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
    Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.